Emergent BioSolutions Inc.
EBS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001367644
No open-market purchases or sales by Emergent BioSolutions Inc. insiders were filed in the last 90 days; 194 institutions reported holding it in 13F filings for Q2 2026, worth $373.6M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Emergent BioSolutions Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 254
- −22 vs. Q3 2021
- Shares held
- 42.8M
- −1.74M (−3.9%) vs. Q3 2021
- Total value
- $1.86B
- −$365.8M (−16.4%) vs. Q3 2021
- New holders
- 47
- 88 more added
- Sold out
- 69
- 94 more reduced
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EBS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 194 | $373.6M |
| Q1 2026 | 190 | $360.7M |
| Q4 2025 | 183 | $536.5M |
| Q3 2025 | 169 | $352.5M |
| Q2 2025 | 161 | $240.9M |
| Q1 2025 | 161 | $176.1M |
| Q4 2024 | 156 | $332.0M |
| Q3 2024 | 140 | $264.5M |
| Q2 2024 | 141 | $207.5M |
| Q1 2024 | 121 | $90.8M |
| Q4 2023 | 134 | $98.2M |
| Q3 2023 | 163 | $140.8M |
| Q2 2023 | 183 | $336.2M |
| Q1 2023 | 192 | $465.3M |
| Q4 2022 | 198 | $545.8M |
| Q3 2022 | 211 | $852.4M |
| Q2 2022 | 233 | $1.28B |
| Q1 2022 | 254 | $1.72B |
| Q4 2021 | 254 | $1.86B |
| Q3 2021 | 277 | $2.23B |
| Q2 2021 | 290 | $2.82B |
| Q1 2021 | 340 | $4.14B |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Emergent BioSolutions Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −1,261−100.0% | Sold out |
| FourThought Financial, LLC | 0 | $0 | 0.00% | −1,264−100.0% | Sold out |
| Creative Financial Designs Inc | 0 | $0 | 0.00% | −1,126−100.0% | Sold out |
| Spire Wealth Management | 0 | $0 | 0.00% | −900−100.0% | Sold out |
| Assetmark, Inc | 0 | $0 | 0.00% | −639−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −481−100.0% | Sold out |
| KBC Group NV | 0 | $0 | 0.00% | −471−100.0% | Sold out |
| Prentice Wealth Management LLC | 0 | $0 | 0.00% | −310−100.0% | Sold out |
| Disciplina Capital Management LLC | 0 | $0 | 0.00% | −303−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −299−100.0% | Sold out |
| Cullen/Frost Bankers, Inc. | 0 | $0 | 0.00% | −282−100.0% | Sold out |
| Bogart Wealth, LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Sandy Spring Bank | 0 | $0 | 0.00% | −175−100.0% | Sold out |
| Neo Ivy Capital Management | 0 | $0 | 0.00% | −117−100.0% | Sold out |
| Smithfield Trust Co | 0 | $0 | 0.00% | −90−100.0% | Sold out |
| O'Shaughnessy Asset Management, LLC | 0 | $0 | 0.00% | −103−100.0% | Sold out |
| IronBridge Private Wealth, LLC | 0 | $0 | 0.00% | −103−100.0% | Sold out |
| Ancora Advisors, LLC | 0 | $0 | 0.00% | −80−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −60−100.0% | Sold out |
| Covington Capital Management | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Leonteq Securities AG | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| Jacobi Capital Management LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Marshall Wace North America L.P. | – | – | – | – | Not filed |